Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290680 · ClinicalTrials.gov registry record · Phase 1
Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00290680 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 36 participants.
The verdict
NCT00290680, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with celecoxib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and celecoxib in treating patients with advanced solid tumors.
Interventions
- DRUG bortezomib
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2005-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290680
The ClinicalTrials.gov registry entry for NCT00290680 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bortezomib is the first listed.
NCT00290680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00290680 about?
NCT00290680 is a clinical study titled "Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors". RATIONALE: Bortezomib and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with celecoxib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and celecoxib in t...
What is the current status of trial NCT00290680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2005-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00290680?
The interventions under investigation include: bortezomib (DRUG), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00290680?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.